R&D Beyond good intentions: How life sciences can prove its read... While support for reducing animal use has never been stronger, the path to broad adoption is steep and complex.
R&D Q4 Clinical trials round-up: October to December 2025 We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.
R&D Big promises, hard work: What 2026 will demand from pharma Eloise McLennan looks at a set of signals areas where pressure is building and 2026 looks set to demand more clarity, discipline, and follow-through.
R&D Clinical research demands agile CROs An emerging consensus across sponsors, investigators, and regulators is that agility must become a defining attribute of CRO performance.
R&D Europe has the tools to fight superbugs. Let’s use them. Data shows countries are off track – increasing the risk of profound health and economic consequences from AMR. Medical technologies can help.
R&D FDA’s emerging framework to reduce animal testing: Implicati... Exploring the strategic shift toward reducing reliance on non-human primates (NHPs) and other animal species in R&D.
Digital Trustworthy and novel AI in clinical trial planning, with Kr... Norstella's Kris Kaneta discusses why patient-level data is pharma's most important asset, as well as expanding the efficacy of AI for clinical trials
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
